Myelodysplastic syndromes: therapeutic problems and decisions (review)

Myelodysplastic syndromes: therapeutic problems and decisions (review)

Show other versions (1)

<p>Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders of myeloid hematopoietic stem cells characterized by an ineffective hematopoiesis associated with cytopenias, morphologic dysplasia and a progression to acute myeloid leukemia. The only potentially curative MDS tr...

Full description

Bibliographic Details
Main Authors:	S. V. Semochkin, T. N. Tolstykh, A. G. Rumyantsev
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkogematologiâ
Subjects:	myelodysplastic syndromes hypomethylating agents lenalidomide azacitidine decytabine
Online Access:	http://oncohematology.abvpress.ru/index.php/ongm/article/view/63

Similar Items

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

Myelodysplastic syndromes: Where do we stand?
by: Nitin Sood, et al.
Published: (2016-01-01)

Myelodysplastic syndrome from theoretical review to clinical application view
by: Amrallah A. Mohammad
Published: (2018-12-01)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: Jonathan Pan, et al.
Published: (2020-10-01)

The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: VN Ovechkina, et al.
Published: (2017-07-01)

Acute Myeloblastic Leukemia and Myelodysplastic Syndrome: Azacitidine for Prophylactic and Preventive Purposes after Allogeneic Hematopoietic Stem Cell Transplantation
by: VN Ovechkina, et al.
Published: (2017-01-01)

Hypomethylating Agents in Oncohematology
by: AD Shirin,, et al.
Published: (2016-10-01)

PREVENTING INFECTIONS IN HIGHER-RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH HYPOMETHYLATION AGENTS
by: Yishai Ofran
Published: (2013-08-01)

Managing myelodysplastic syndromes in very old patients: a teaching case report
by: Niscola P, et al.
Published: (2013-04-01)

INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY
by: Giuseppe Leone, et al.
Published: (2018-07-01)

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies
by: Nina Kim, et al.
Published: (2018-08-01)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
by: Francesco Pisani, et al.
Published: (2014-04-01)

Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
by: Vincent Jachiet, et al.
Published: (2021-05-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report
by: Gerasimos Evangelatos, et al.
Published: (2017-01-01)

Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach
by: Ana María Hurtado López, et al.
Published: (2020-01-01)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
by: Wang Eunice S, et al.
Published: (2012-11-01)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
by: Ritchie EK
Published: (2012-06-01)

Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report
by: Kentaro Serizawa, et al.
Published: (2018-06-01)

Clinical Results of Hypomethylating Agents in AML Treatment
by: Marjan Cruijsen, et al.
Published: (2014-12-01)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
by: António Almeida, et al.
Published: (2017-01-01)

The Impact of the Epigenetic Cancer Drug Azacitidine on Host Immunity: The Role of Myelosuppression, Iron Overload and <i>tp53</i> Mutations in a Zebrafish Model
by: Shu-Ching Wang, et al.
Published: (2019-09-01)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
by: Marion Divoux, et al.
Published: (2020-09-01)

Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8
by: Nahoko Tanaka, et al.
Published: (2019-11-01)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Kah Keng Wong, et al.
Published: (2021-02-01)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
by: Hassan A. Al-Jafar, et al.
Published: (2012-10-01)

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors
by: Yu‐Qian Sun, et al.
Published: (2021-04-01)

Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report
by: Antoine Ponard, et al.
Published: (2018-07-01)

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
by: Jiale Ma, et al.
Published: (2021-08-01)

AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.
by: Pasquale Niscola
Published: (2014-02-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
by: Maria Luisa Palacios-Berraquero, et al.
Published: (2021-05-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-03-01)

A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
by: Elena Elli, et al.
Published: (2012-01-01)

Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis
by: Tomoya Maeda, et al.
Published: (2021-01-01)

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy
by: Jina Yun, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_bl26eqq166vc4tvm5hrgi5h8vo